Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer-Drug Carriers Matter

Area of Science:

• Oncology
• Molecular Biology
• Therapeutics

Background:

• Signal transducer and transcription activator 3 (STAT3) is highly expressed and phosphorylated in various cancers, correlating with disease progression and poor prognosis.
• Constitutive STAT3 activation drives cancer hallmarks like proliferation, metastasis, and drug resistance, making it a key therapeutic target.
• Existing STAT3 inhibitors face limitations due to upstream reactivation and low specificity.

Purpose of the Study:

• To review oligonucleotide-based therapeutics targeting STAT3 activity in cancer.
• To summarize the impact of nucleic acid-based STAT3 inhibition on cancer therapy.
• To highlight the role of delivery carriers for enhancing oligonucleotide efficacy.

Main Methods:

• Review of preclinical and clinical studies on oligonucleotide-based therapeutics (siRNA, shRNA, ASO, ODN-decoy) targeting STAT3.
• Analysis of STAT3 pathway regulation by non-coding nucleic acids.
• Evaluation of nanoparticle-based delivery systems for nucleic acid therapeutics.

Main Results:

• Oligonucleotide-based therapeutics demonstrate potential in silencing STAT3 and modifying cancer gene expression.
• Studies show inhibition of STAT3 by nucleic acid-based therapeutics affects various cancer therapies.
• Delivery systems, particularly functionalized nanoparticles, are crucial for enhancing the efficacy of oligonucleotide therapeutics in cancer cells and the tumor microenvironment.

Conclusions:

• Oligonucleotide-based therapeutics represent a promising strategy for targeting STAT3 in cancer.
• Effective delivery systems are essential to overcome limitations and maximize the therapeutic potential of these agents.
• Combining specific oligonucleotides with targeted nanoparticles can create highly efficient anti-cancer formulations.